Company intelligence / Profile preview
Rectify Pharmaceuticals, Inc.
Cambridge, Massachusetts, United Statesrectifypharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate RTY-694 has shown positive preclinical results in PSC models, improving bile composition and reducing inflammation and fibrosis. The company plans to start first-in-human trials in 2025 and aims to conduct a Phase 2a proof-of-mechanism study in PSC patients.
- Therapeutic areas
- GastroenterologyCardiovascularNeurology
- Modalities
- Small molecules (oral)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Rectify Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rectify Pharmaceuticals, Inc..